# US 2015/0148374 A1 · Complement pathway modulators and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148374 A1
- Document ID: US20150148374A1
- Status: Published application
- Kind: A1
- Application number: 14/409,914
- Filed: 2013-06-27
- Published: 2015-05-28
- Earliest claimed: 2012-07-12
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Ulrich Hommel; Edwige Liliane Jeanne Lorthiois; Jeurgen Klaus Maibaum; Nils Ostermann; Stefan Andreas Randl; Olivier Rogel; Anna Vulpetti
- Web page: https://patentgrep.com/patent/US20150148374A1

## CPC

- C07D 403/14: containing three or more hetero rings
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 7/06: Antianaemics
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 33/00: Antiparasitic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

## Claims

### Claim 1

A compound or a salt thereof according to Formula I:
wherein
A is a group selected from:
Z1 is C(R1) or N;
Z2 is C(R2) or N;
Z3 is C(R3) or N, wherein at least one of Z1, Z2 or Z3 is not N;
R1 is selected from the group consisting of hydrogen, halogen, C1-C6alkyl, C1-C6alkoxy, haloC1-C6alkyl, haloC1-C6alkoxy C1-C6alkoxycarbonyl, CO2H and C(O)NRARB;
R2 and R3 are independently selected from the group consisting of hydrogen, halogen, hydroxy, NRCRD, cyano, CO2H, CONRARB, SO2C1-C6alkyl, and SO2NH2, SO2NRARB, C1-C6alkoxycarbonyl, —C(NRA)NRCRD, C1-C6alkyl, C3-C6cycloalkyl, haloC1-C6alkyl, C2-C6alkenyl, C1-C6alkoxy, haloC1-C6alkoxy, C2-C6alkenyloxy, wherein each alkyl, alkenyl, alkoxy and alkenyloxy is unsubstituted or substituted with up to 4 substitutents independently selected from halogen, hydroxy, cyano, tetrazole, C1-C4alkoxy, C1-C4haloalkoxy, CO2H, C1-C6alkoxycarbonyl, C(O)NRARB, NRCRD, optionally substituted phenyl, heterocycle having 4 to 7 ring atoms and 1, 2, or 3 ring heteroatoms selected from N, O or S, heteroaryl having 5 or 6 ring atoms and 1 or 2 or 3 ring heteroatoms selected from N, O or S, and wherein optional phenyl and heteroaryl substituents are selected from halogen, hydroxy, C1-C4alkyl, C1-C4alkoxy and CO2H;
R5 is C1-C4alkyl, hydroxyC1-C4alkyl, haloC1-C4alkyl, C1-C4alkoxyC1-C4alkyl, amino, methylamino;
X1 is CR9R22 or sulfur;
X2 is CR7R8, oxygen, sulfur, N(H) or N(C1-C6alkyl), wherein at least one of X1 and X2 is carbon; or
X1 and X2, in combination, forms an olefin of the formula —C(R7)═C(H)— or —C(R7)═C(C1-C4alkyl)-, wherein the C(R7) is attached to X3;
X3 is (CR6R21)q or N(H) wherein q is 0, 1 or 2, wherein X3 is CR6R21 or (CR6R21)2 when either X1 or X2 is sulfur or X2 is oxygen; or
X2 and X3, taken in combination, are —N═C(H)— or —N═C(C1-C4alkyl)- in which the C(H) or C(C1-C4alkyl) is attached to X1;
R6 is selected at each occurrence from hydrogen and C1-C6alkyl;
R7 is hydrogen, halogen, hydroxy, cyano, C1-C6alkyl, C1-C6alkoxy, hydroxyC1-C6alkyl, C1-C6alkoxyC1-C6alkyl, haloC1-C6alkyl, or C1-C6haloalkoxy;
R8 is hydrogen, halogen, hydroxy, azide, cyano, COOH, C1-C6alkoxycarbonyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, C1-C6haloalkoxy, NRARB, N(H)C(O)C1-C6alkyl, hydroxyC1-C6alkyl, C1-C6alkoxyC1-C6alkyl, or C1-C6alkyl substituted with NRARB, N(H)C(O)H or N(H)C(O)(C1-C4alkyl);
R9 is selected from the group consisting of hydrogen, hydroxy, halogen, C1-C6alkyl, haloC1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkoxy, haloC1-C6alkoxy, NRARB, N(H)C(O)C1-C6alkyl, N(H)C(O)OC1-C6alkyl and OC(O)NRCRD each of alkyl, alkoxy, alkenyl, and alkynyl substituents may be substituted with 0, 1, or 2 groups independently selected at each occurrence from the group consisting of halogen, hydroxy, C1-C6alkyl, C1-C6alkoxy, and NRARB;
R20 is hydrogen or C1-C6alkyl;
R21 is selected at each occurrence from the group consisting of hydrogen, phenyl and C1-C6alkyl, which alkyl group is unsubstituted or substituted with hydroxy, amino, azide, and NHC(O)C1-C6alkyl;
R22 is selected from the group consisting of hydrogen, halogen, hydroxy, amino and C1-C6alkyl;
CR7R8, taken in combination forms a spirocyclic 3 to 6 membered carbocycle which is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halogen and methyl; or
R7 and R8, taken in combination, form an exocyclic methylidene (═CH2);
R7 and R22 or R8 and R9, taken in combination form an epoxide ring or a 3 to 6 membered carbocyclic ring system which carbocyclic ring is substituted with 0, 1, or 2 substituents independently selected from the group consisting of halogen, methyl, ethyl, hydroxyC1-C4alkyl, C1-C6alkoxyC1-C4alkyl, C1-C4alkoxycarbonyl, CO2H, and C1-C4alkyl substituted with NRARB;
R6 and R7 or R8 and R21, taken in combination, form a fused 3 membered carbocyclic ring system which is substituted with 0, 1 or 2 substituents independently selected from the group consisting of halogen, methyl, ethyl, hydroxyC1-C4alkyl, C1-C6alkoxyC1-C4alkyl, C1-C4alkoxycarbonyl, CO2H, and C1-C4alkyl substituted with NRARB; or
R20 and R22 taken in combination form a fused 3 carbocyclic ring system;
R9 and R21 taken in combination form a form 1 to 3 carbon alkylene linker;
R7 and R20 taken in combination form 1 to 3 carbon alkylene linker;
R10 is C1-C4alkyl, C3-C6cycloalkyl, C3-C6cycloalkylC1-C4alkyl, or haloC1-C3alkyl;
W1 is C(R11) or N;
W2 is C(R12) or N;
W3 is C(R13) or N;
R11 and R13 are independently selected from the group consisting of hydrogen, halogen, C1-C6alkyl;
R12 is hydrogen, halogen, C1-C4alkyl, C3-C7cycloalkyl, C1-C4alkoxy, C1-C4haloalkyl, cyano, hydroxy, CO2H, CO2Me, CONRARB or phenyl;
RA and RB are independently selected from the group consisting of hydrogen, and C1-C6alkyl, haloC1-C6alkyl, C1-C6alkoxyC1-C6alkyl, hydroxyC1-C6alkyl, or NRARB, taken in combination, form a heterocycle having 4 to 7 ring atoms and 0 or 1 additional ring N, O or S atoms, which heterocycle is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-C4alkyl, halogen, hydroxy, C1-C4alkoxy; and
RC and RD, are each independently selected from the group consisting of hydrogen and C1-C6alkyl, haloC1-C6alkyl, C1-C6alkoxyC1-C6alkyl, or hydroxyC1-C6alkyl.

### Claim 2

A compound or a salt thereof according to Formula II:
wherein
A is a group selected from:
Z1 is C(R1) or N;
Z2 is C(R2) or N;
Z3 is C(R3) or N, wherein at least one of Z1, Z2 or Z3 is not N;
R1 is selected from the group consisting of hydrogen, halogen, C1-C6alkyl, C1-C6alkoxy, haloC1-C6alkyl, haloC1-C6alkoxy C1-C6alkoxycarbonyl, CO2H and C(O)NRARB;
R2 and R3 are independently selected from the group consisting of hydrogen, halogen, hydroxy, NRCRD, cyano, CO2H, CONRARB, SO2C1-C6alkyl, and SO2NH2, SO2NRARB, C1-C6alkoxycarbonyl, —C(NRA)NRCRD, C1-C6alkyl, C3-C6cycloalkyl, haloC1-C6alkyl, C2-C6alkenyl, C1-C6alkoxy, haloC1-C6alkoxy, C2-C6alkenyloxy, wherein each alkyl, alkenyl, alkoxy and alkenyloxy is unsubstituted or substituted with up to 4 substitutents independently selected from halogen, hydroxy, cyano, tetrazole, C1-C4alkoxy, C1-C4haloalkoxy, CO2H, C1-C6alkoxycarbonyl, C(O)NRARB, NRCRD, optionally substituted phenyl, heterocycle having 4 to 7 ring atoms and 1, 2, or 3 ring heteroatoms selected from N, O or S, heteroaryl having 5 or 6 ring atoms and 1 or 2 or 3 ring heteroatoms selected from N, O or S, and wherein optional phenyl and heteroaryl substituents are selected from halogen, hydroxy, C1-C4alkyl, C1-C4alkoxy and CO2H;
R5 is C1-C4alkyl, hydroxyC1-C4alkyl, haloC1-C4alkyl, C1-C4alkoxyC1-C4alkyl, amino, methylamino;
R6 is hydrogen;
R7 is hydrogen or fluoro;
R8 is hydrogen, methyl or hydroxymethyl;
R9 is hydrogen, halogen, hydroxy or C1-C4alkoxy; or
R6 and R7, taken in combination, form a cyclopropane ring; or
R8 and R9, taken in combination, form a cyclopropane ring;
R10 is C1-C4alkyl, C3-C6cycloalkyl-methyl or haloC1-C3alkyl;
W1 is C(R11) or N;
W2 is C(R12) or N;
W3 is C(R13) or N;
R11 and R13 are independently selected from the group consisting of hydrogen, halogen, C1-C6alkyl;
R12 is hydrogen, halogen, C1-C4alkyl, C3-C7cycloalkyl, C1-C4alkoxy, C1-C4haloalkyl, cyano, hydroxy, CO2H, CO2Me, CONRARB or phenyl;
RA and RB are independently selected from the group consisting of hydrogen, and C1-C6alkyl, haloC1-C6alkyl, C1-C6alkoxyC1-C6alkyl, hydroxyC1-C6alkyl, or NRARB, taken in combination, form a heterocycle having 4 to 7 ring atoms and 0 or 1 additional ring N, O or S atoms, which heterocycle is substituted with 0, 1, or 2 substituents independently selected from the group consisting of C1-C4alkyl, halogen, hydroxy, C1-C4alkoxy; and
RC and RD, are each independently selected from the group consisting of hydrogen and C1-C6alkyl, haloC1-C6alkyl, C1-C6alkoxyC1-C6alkyl, or hydroxyC1-C6alkyl.

### Claim 3 (depends on 2)

The compound, or salt thereof, according to claim 2, wherein the compound is represented by Formula III or Formula IV:

### Claim 4 (depends on 1)

The compound, or salt thereof, of claim 1, wherein Z1 is N or CR1; Z2 is N or CR2 and Z3 is N or CR3 wherein at least one of Z1, Z2 and Z3 are not N;
R1 is hydrogen, halogen or C1-C4alkyl;
R2 is selected from the group consisting of hydrogen, halogen, CO2H, C1-C4alkyl and C1-C4alkoxy;
R3 is selected from the group consisting of hydrogen, halogen, CO2H, C1-C4alkyl, C3-C5cycloalkyl, haloC1-C4alkyl and C1-C4alkoxy, wherein the alkoxy is optionally substituted by pyridyl or pyrimidinyl; and
R5 is amino or C1-C4alkyl.

### Claim 5 (depends on 1)

The compound, or salt thereof, of claim 1, wherein Z1 is CH; Z2 is CH or N; Z3 is CR3; and
R3 is hydrogen, C1-C4alkyl, or C1-C4alkoxy, wherein the alkoxy is optionally substituted by pyridyl or pyrimidinyl.

### Claim 6 (depends on 1)

The compound, or salt thereof, of claim 1, wherein R6 and R7 taken in combination form a cyclopropane ring;
R8, R9 and R22 are hydrogen.

### Claim 7 (depends on 1)

The compound, or salt thereof, of claim 1, wherein W1 and W2 are CH;
W3 is N; and
R10 is haloC1-C2alkyl.

### Claim 8 (depends on 1)

The compound, or salt thereof, of claim 1, wherein W1 and W2 are CH;
W3 is N; and
R10 is 2,2,2-trifluoroethyl.

### Claim 9 (depends on 1)

The compound, or salt thereof, of claim 1, wherein W1 and W2 are CH;
W3 is N; and
R10 is per-deutero-2,2,2-trifluoroethyl.

### Claim 10 (depends on 1)

The compound, or salt thereof, of claim 1, or a salt thereof, represented by formula (V) or (VI):
wherein
Z2 is CR2 or N;
R2 is hydrogen, C1-C4alkyl, or halogen;
R3 is hydrogen, C1-C4alkyl, or pyrimidinylmethoxy;
R5 is methyl or amino; and
R10 is C1-C4alkyl, C3-C6cycloalkyl-methyl or C1-C2haloalkyl.

### Claim 11 (depends on 2)

The compound of claim 2, or a salt thereof, selected from the group consisting of:
1-(2-oxo-2-((1R,3S,5R)-3-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)ethyl)-1H-indazole-3-carboxamide;
1-(2-oxo-2-((1R,3S,5R)-3-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)ethyl)-1H-pyrazolo[3,4-c]pyridine-3-carboxamide;
(1R,3S,5R)-2-(2-(3-acetyl-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide; and
(1R,3S,5R)—N2-(1-carbamoyl-1H-indol-3-yl)-N3-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxamide.

### Claim 12 (depends on 2)

The compound of claim 2, or a salt thereof, which is 1-(2-((1R,3S,5R)-3-(1-isopropyl-1H-pyrazol-3-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazole-3-carboxamide.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers and a therapeutically effective amount of a compound of claim 1.

### Claim at position 14

14-15. (canceled)

### Claim 16 (depends on 1)

A method of treating a disorder or a disease in a subject mediated by complement activation, in particular mediated by activation of the complement alternative pathway, wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to claim 1.

### Claim 17 (depends on 16)

The method of claim 16, in which the disease or disorder is selected from the group consisting of age-related macular degeneration, geographic atrophy, diabetic retinopathy, uveitis, retinitis pigmentosa, macular edema, Behcet's uveitis, multifocal choroiditis, Vogt-Koyangi-Harada syndrome, intermediate uveitis, birdshot retino-chorioditis, sympathetic ophthalmia, ocular dicatricial pemphigoid, ocular pemphigus, nonartertic ischemic optic neuropathy, post-operative inflammation, retinal vein occlusion, neurological disorders, multiple sclerosis, stroke, Guillain Barre Syndrome, traumatic brain injury, Parkinson's disease, disorders of inappropriate or undesirable complement activation, hemodialysis complications, hyperacute allograft rejection, xenograft rejection, interleukin-2 induced toxicity during IL-2 therapy, inflammatory disorders, inflammation of autoimmune diseases, Crohn's disease, adult respiratory distress syndrome, myocarditis, post-ischemic reperfusion conditions, myocardial infarction, balloon angioplasty, post-pump syndrome in cardiopulmonary bypass or renal bypass, atherosclerosis, hemodialysis, renal ischemia, mesenteric artery reperfusion after aortic reconstruction, infectious disease or sepsis, immune complex disorders and autoimmune diseases, rheumatoid arthritis, systemic lupus erythematosus (SLE), SLE nephritis, proliferative nephritis, liver fibrosis, hemolytic anemia, myasthenia gravis, tissue regeneration, neural regeneration, dyspnea, hemoptysis, ARDS, asthma, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary embolisms and infarcts, pneumonia, fibrogenic dust diseases, pulmonary fibrosis, asthma, allergy, bronchoconstriction, hypersensitivity pneumonitis, parasitic diseases, Goodpasture's Syndrome, pulmonary vasculitis, Pauci-immune vasculitis, immune complex-associated inflammation, antiphospholipid syndrome, glomerulonephritis and obesity.

### Claim at position 17

18-22. (canceled)
